Clinical Trial Update: Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial of Respimat Combivent for chronic obstructive pulmonary disease has completed and results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Combivent (ipratropium bromide/albuterol) (ipratropium bromide and albuterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2009-06-01